Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Macaca fascicularis | B1 bradykinin receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Onchocerca volvulus | B1 bradykinin receptor | 352 aa | 314 aa | 22.0 % | |
Loa Loa (eye worm) | G protein-coupled receptor | B1 bradykinin receptor | 352 aa | 360 aa | 20.6 % |
Echinococcus granulosus | growth hormone secretagogue receptor type 1 | B1 bradykinin receptor | 352 aa | 341 aa | 23.2 % |
Schistosoma japonicum | ko:K04209 neuropeptide Y receptor, invertebrate, putative | B1 bradykinin receptor | 352 aa | 307 aa | 23.8 % |
Brugia malayi | putative neuropeptide receptor NPR1 | B1 bradykinin receptor | 352 aa | 343 aa | 24.5 % |
Loa Loa (eye worm) | hypothetical protein | B1 bradykinin receptor | 352 aa | 309 aa | 24.6 % |
Echinococcus granulosus | allatostatin A receptor | B1 bradykinin receptor | 352 aa | 311 aa | 25.7 % |
Onchocerca volvulus | B1 bradykinin receptor | 352 aa | 310 aa | 22.6 % | |
Loa Loa (eye worm) | neuropeptide F receptor | B1 bradykinin receptor | 352 aa | 327 aa | 26.9 % |
Echinococcus multilocularis | allatostatin A receptor | B1 bradykinin receptor | 352 aa | 311 aa | 25.7 % |
Onchocerca volvulus | B1 bradykinin receptor | 352 aa | 331 aa | 19.0 % | |
Echinococcus granulosus | thyrotropin releasing hormone receptor | B1 bradykinin receptor | 352 aa | 338 aa | 21.9 % |
Echinococcus multilocularis | thyrotropin releasing hormone receptor | B1 bradykinin receptor | 352 aa | 338 aa | 21.0 % |
Schistosoma mansoni | opsin-like receptor | B1 bradykinin receptor | 352 aa | 298 aa | 25.2 % |
Echinococcus multilocularis | g protein coupled receptor | B1 bradykinin receptor | 352 aa | 332 aa | 21.4 % |
Onchocerca volvulus | Mitochondrial inner membrane protein homolog | B1 bradykinin receptor | 352 aa | 341 aa | 22.9 % |
Schistosoma mansoni | peptide (allatostatin)-like receptor | B1 bradykinin receptor | 352 aa | 318 aa | 23.9 % |
Onchocerca volvulus | B1 bradykinin receptor | 352 aa | 284 aa | 25.0 % | |
Echinococcus granulosus | neuropeptide receptor | B1 bradykinin receptor | 352 aa | 313 aa | 25.9 % |
Schistosoma mansoni | neuropeptide receptor | B1 bradykinin receptor | 352 aa | 307 aa | 22.8 % |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | B1 bradykinin receptor | 352 aa | 333 aa | 21.0 % |
Schistosoma japonicum | Rhodopsin, putative | B1 bradykinin receptor | 352 aa | 326 aa | 22.1 % |
Onchocerca volvulus | B1 bradykinin receptor | 352 aa | 294 aa | 23.8 % | |
Onchocerca volvulus | B1 bradykinin receptor | 352 aa | 318 aa | 25.2 % | |
Echinococcus multilocularis | growth hormone secretagogue receptor type 1 | B1 bradykinin receptor | 352 aa | 354 aa | 22.0 % |
Onchocerca volvulus | B1 bradykinin receptor | 352 aa | 380 aa | 20.8 % | |
Echinococcus multilocularis | neuropeptide receptor | B1 bradykinin receptor | 352 aa | 313 aa | 25.6 % |
Onchocerca volvulus | B1 bradykinin receptor | 352 aa | 323 aa | 23.5 % | |
Loa Loa (eye worm) | hypothetical protein | B1 bradykinin receptor | 352 aa | 318 aa | 22.3 % |
Brugia malayi | G-protein coupled receptor | B1 bradykinin receptor | 352 aa | 282 aa | 23.4 % |
Schistosoma japonicum | ko:K04134 cholinergic receptor, invertebrate, putative | B1 bradykinin receptor | 352 aa | 326 aa | 22.4 % |
Onchocerca volvulus | Programmed cell death protein 5 homolog | B1 bradykinin receptor | 352 aa | 283 aa | 20.5 % |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 524 nM | Antagonist activity at Cynomolgus monkey bradykinin B1 receptor expressed in CHO cells assessed as calcium transient by FLIPR assay | ChEMBL. | 18752949 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.